You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
NOXICID is indicated for: 1. Gastro-Oesophageal Reflux Disease (GORD) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (GORD) 2. Patients requiring NSAID therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk. 3. Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion 4. In combination with appropriate antibiotics for: - healing of duodenal ulcer associated with Helicobacter pylori - eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
White to cream coloured pellets filled in hard gelatin capsule with brown cap and brown body, imprinted with 'MYLAN' over 'EM 40' in black ink on cap and body
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
NOXICID is indicated for: 1. Gastro-Oesophageal Reflux Disease (GORD) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (GORD) 2. Patients requiring NSAID therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk. 3. Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion 4. In combination with appropriate antibiotics for: - healing of duodenal ulcer associated with Helicobacter pylori - eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
White to cream coloured pellets filled in hard gelatin capsule with pink cap and pink body, imprinted with 'MYLAN' over 'EM 20' in black ink on cap and body
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
NOXICID is indicated for: 1. Gastro-Oesophageal Reflux Disease (GORD) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (GORD) 2. Patients requiring NSAID therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk. 3. Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion 4. In combination with appropriate antibiotics for: - healing of duodenal ulcer associated with Helicobacter pylori - eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
White to cream coloured pellets filled in hard gelatin capsule with pink cap and pink body, imprinted with 'MYLAN' over 'EM 20' in black ink on cap and body
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
NOXICID is indicated for: 1. Gastro-Oesophageal Reflux Disease (GORD) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (GORD) 2. Patients requiring NSAID therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk. 3. Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion 4. In combination with appropriate antibiotics for: - healing of duodenal ulcer associated with Helicobacter pylori - eradication of Helicobacter pylori in patients with active or healed peptic ulcer.
White to cream coloured pellets filled in hard gelatin capsule with brown cap and brown body, imprinted with 'MYLAN' over 'EM 40' in black ink on cap and body
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.